Gynaecological cancer (clinical) DSS Metadata Online Registry (METeOR)

Descripción

Person with cancer—cytopathology result, code N Maximum occurences: 29 Identifying and definitional attributes Short name: Cytopathology result Synonymous names: Cytology result METeOR identifier: 422463 Registration status: Health, Standard 08/05/2014 Definition: The result of a cytopathology test to verify cancer diagnosis and morphology in a person with cancer, as represented by a code. Data Element Concept: Person with cancer—cytopathology result Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Positive 2 Negative 3 Equivocal Supplementary values: 7 Not applicable 9 Not available Collection and usage attributes Guide for use: CODE 1 Positive A positive result indicates that the cellular abnormality tested for was found. In the case of cancer diagnosis, a positive result indicates malignancy. CODE 2 Negative A negative result indicates that the cellular abnormality tested for was not found. CODE 3 Equivocal This code should be recorded when the cellular abnormality status could not be determined by the test. CODE 9 Not available This code should be recorded when the test results have not been received or could not be accessed. Source and reference attributes Submitting organisation: Cancer Australia Data element attributes Collection and usage attributes Guide for use: Record the code specifying the positivity or negativity of cytology or cytopathology test results as outlined in the pathology report. Where multiple tests have been undertaken record each test result separately. A negative result indicates that no abnormal cells were found in the sample tested. A positive result indicates that there were abnormal cells found in the sample tested. This includes results of peritoneal washings. Collection methods: Collected for people with cancer who have undergone a cytology or cytopathology test to help define the proportion of cancer morphologically verified. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Gynaecological Cancer DSS Working Group, Cancer Australia. 2010 Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person with cancer—lymphovascular invasion indicator, yes/no code N Identifying and definitional attributes Short name: Lymphovascular invasion indicator METeOR identifier: 519212 Registration status: Health, Standard 08/05/2014 Definition: An indicator of whether there is evidence of the invasion of cancer cells into blood vessels and/or the lymphatic system in the person with cancer, as represented by a code. Data Element Concept: Person with cancer—lymphovascular invasion indicator Value domain attributes Representational attributes Representation class: Code Data type: Boolean Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Data element attributes Collection and usage attributes Guide for use: An indicator of whether there is evidence of invasion of cancer cells into blood vessels and/or the lymphatic system. Lymphovascular involvement usually precedes spread to the lymph nodes and hence is a predictor of lymph node metastases, although its value as a prognostic indicator is related to cancer type. Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015 Lung cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

boolean

Descripción

Person with cancer—location of lymphovascular invasion of cervix, code N Obligation: Conditional, Maximum occurences: 5 Identifying and definitional attributes Short name: Cervical lymphovascular invasion location Synonymous names: Cervical LVI location; LVI of cervix METeOR identifier: 424175 Registration status: Health, Standard 08/05/2014 Definition: The location of cancer cells invasion into the lymphatic and/or vascular spaces for a person with cervical cancer, as represented by a code. Context: Invasion of lymphatic vascular space is a predictor of lymph node metastasis and recurrence. Collect this information for women with cervical cancer. Data Element Concept: Person with cancer—location of lymphovascular invasion Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Lymphovascular invasion present and at tumour interface 2 Lymphovascular invasion present and within cervix remote from tumour interface 3 Lymphovascular invasion present (location unknown) Supplementary values: 7 Not applicable-pathology specimen not obtained or no lymphovascular invasion present 8 Unknown whether pathology specimen obtained 9 Pathology specimen obtained but lymphovascular invasion not stated/inadequately described Source and reference attributes Submitting organisation: Cancer Australia Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is only to be recorded for patients with cervical cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N, and when Person with cancer—lymphovascular invasion indicator, yes/no code N indicates the presence of lymphovascular invasion. Data element attributes Collection and usage attributes Guide for use: Record the one digit code indicating the location of lymphovascular invasion in a woman with cervical cancer. Collection methods: Collect from pathology reports or databases. Source and reference attributes Submitting organisation: Cancer Australia Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person with cancer—location of lymphovascular invasion of corpus uteri, code N Obligation: Conditional, Maximum occurences: 5 Identifying and definitional attributes Short name: Corpus uteri lymphovascular invasion location Synonymous names: LVI of corpus uteri METeOR identifier: 424445 Registration status: Health, Standard 08/05/2014 Definition: The location of cancer cells invasion into the lymphatic and/or vascular spaces for a person with cancer of the corpus uteri, as represented by a code. Context: Invasion of lymphatic vascular space is a predictor of lymph node metastasis and recurrence. Collect this item for women with cancer of the corpus uteri. Data Element Concept: Person with cancer—location of lymphovascular invasion Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Lymphovascular invasion present and at tumour interface 2 Lymphovascular invasion present and within the myometrium remote to the tumour interface 3 Lymphovascular invasion present (location unknown) Supplementary values: 7 Not applicable-pathology specimen not obtained or no lymphovascular invasion present 8 Unknown whether pathology specimen obtained 9 Pathology specimen obtained but lymphovascular invasion not stated/inadequately described Source and reference attributes Submitting organisation: Cancer Australia Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is only to be recorded for patients with endometrial cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N, and when Person with cancer—lymphovascular invasion indicator, yes/no code N indicates the presence of lymphovascular invasion. Data element attributes Collection and usage attributes Guide for use: Record the 1 digit code indicating the location of lymphovascular invasion of neoplastic (cancer) cells. Lymphovascular invasion of neoplastic cells, both at the interface of the tumour, with the normal myometrium and more distantly, relates partly to tumour invasive depth and partly to tumour type. Collection methods: Collect from pathology reports or databases. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: RCPA (2011), Endometrial Cancer Structured Reporting Protocol (1st Edition 2011) Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person with cancer—extent of primary cancer, cervical cancer staging (FIGO) code N[N] Obligation: Conditional Identifying and definitional attributes Short name: FIGO cervical cancer stage METeOR identifier: 424190 Registration status: Health, Standard 08/05/2014 Definition: The extent of a primary cervical cancer as outlined by International Federation of Gynecology and Obstetrics (FIGO), represented by a code. Context: Collect for women with cervical cancer. Data Element Concept: Person with cancer—extent of primary cancer Value domain attributes Representational attributes Classification scheme: International Federation of Gynecology and Obstetrics cancer staging system Representation class: Code Data type: Number Format: N[N] Maximum character length: 2 Permissible values: Value Meaning 1 Stage IA1 2 Stage IA2 3 Stage IB1 4 Stage IB2 5 Stage IIA1 6 Stage IIA2 7 Stage IIB 8 Stage IIIA 9 Stage IIIB 10 Stage IVA 11 Stage IVB Supplementary values: 99 Not available/inadequately described Collection and usage attributes Guide for use: International Federation of Gynecology and Obstetrics (FIGO) stage according to 2009 definitions. Data on patients affected by Stage 0 disease is not collected. Stage I: the carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded). Stage IA: invasive carcinoma that can be diagnosed only by microscopy, with deepest invasion less than or equal to 5 mm and largest extension less than or equal to 7 mm. CODE 1 Stage IA1 Measured stromal invasion of less than or equal to 3.0 mm in depth and extension of less than or equal to 7.0 mm. CODE 2 Stage IA2 Measured stromal invasion of greater than 3.0 mm and less than 5.0 mm with an extension of not more than 7.0 mm. Stage IB: clinically visible lesions limited to the cervix uteri or preclinical cancers greater than stage IA. CODE 3 Stage IB1 Clinically visible lesion less than or equal to 4.0 cm in greatest dimension. CODE 4 Stage IB2 Clinically visible lesion greater than 4.0 cm in greatest dimension. Stage II: cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina. Stage IIA: without parametrial invasion. CODE 5 Stage IIA1 Clinically visible lesion less than or equal to 4.0 cm in greatest dimension. CODE 6 Stage IIA2 Clinically visible lesion greater than 4.0 cm in greatest dimension. CODE 7 Stage IIB With obvious parametrial invasion. Stage III: the tumour extends to the pelvic wall and/or involves lower third of the vagina and/or causes hydronephrosis or non-functioning kidney. CODE 8 Stage IIIA Tumour involves lower third of the vagina, with no extension to the pelvic wall. CODE 9 Stage IIIB Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney. Stage IV: the carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to Stage IV. CODE 10 Stage IVA Spread of the growth to adjacent organs. CODE 11 Stage IVB Spread to distant organs. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Mutch, D G (2009). The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic Oncology. 115: 325–328 Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is only to be recorded for patients with cervical cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. Data element attributes Collection and usage attributes Guide for use: Record the extent of the primary cervical cancer as outlined by the International Federation of Gynecology and Obstetrics (FIGO) stage. This should be filled out according to 2009 definitions. Data on patients affected by Stage 0 disease is not collected. Collection methods: To be sought from pathology reports or patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Mutch, D G (2009). The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic Oncology. 115: 325–328 Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person with cancer—extent of primary cancer, endometrial cancer staging (FIGO) code N[N] Obligation: Conditional Identifying and definitional attributes Short name: FIGO endometrial cancer stage METeOR identifier: 424209 Registration status: Health, Standard 08/05/2014 Definition: The extent of a primary endometrial cancer as outlined by International Federation of Gynecology and Obstetrics (FIGO), represented by a code. Data Element Concept: Person with cancer—extent of primary cancer Value domain attributes Representational attributes Classification scheme: International Federation of Gynecology and Obstetrics cancer staging system Representation class: Code Data type: Number Format: N[N] Maximum character length: 2 Permissible values: Value Meaning 1 Stage IA 2 Stage IB 3 Stage II 4 Stage IIIA 5 Stage IIIB 6 Stage IIIC1 7 Stage IIIC2 8 Stage IVA 9 Stage IVB Supplementary values: 99 Not available/inadequately described Collection and usage attributes Guide for use: The International Federation of Gynecology and Obstetrics (FIGO) endometrial cancer stage according to 2009 definitions. Stage I: tumour confined to the corpus uteri. CODE 1 Stage IA No invasion or less than half myometrial invasion. CODE 2 Stage IB Invasion equal to or greater than half of the myometrium. Stage II CODE 3 Stage II Tumour invades cervical stroma, but does not extend beyond the uterus. Note: In situ involvement of the endocervix that does not invade the stroma is not a Stage II lesion. Stage III: local and/or regional spread of the tumour. CODE 4 Stage IIIA Tumour invades the serosa of the corpus uteri and/or the adnexa. CODE 5 Stage IIIB Involvement of the vagina, parametrium and/or the pelvic peritoneum. Stage IIIC: retroperitoneal node involvement CODE 6 Stage IIIC1 Pelvic node involvement. CODE 7 Stage IIIC2 Paraaortic involvement. Stage IV: tumour invades bladder and/or bowel mucosa, and/or distant metastases. CODE 8 Stage IVA Tumour invasion of bladder and/or bowel mucosa. CODE 9 Stage IVB Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Mutch, D G (2009). The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic Oncology. 115: 325–328 Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is only to be recorded for patients with endometrial cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. Data element attributes Collection and usage attributes Guide for use: Record the extent of the primary endometrial cancer as outlined by the International Federation of Gynecology and Obstetrics (FIGO) stage. This should be filled out according to 2009 definitions. Collection methods: To be sought from pathology reports or patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Mutch, D G (2009). The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic Oncology. 115: 325–328 Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person with cancer—extent of primary cancer, ovarian cancer staging (FIGO) code N[N] Obligation: Conditional Identifying and definitional attributes Short name: FIGO ovarian cancer stage METeOR identifier: 424212 Registration status: Health, Standard 08/05/2014 Definition: The extent of a primary ovarian cancer as outlined by International Federation of Gynecology and Obstetrics (FIGO), as represented by a code. Data Element Concept: Person with cancer—extent of primary cancer Value domain attributes Representational attributes Classification scheme: International Federation of Gynecology and Obstetrics cancer staging system Representation class: Code Data type: Number Format: N[N] Maximum character length: 2 Permissible values: Value Meaning 1 Stage IA 2 Stage IB 3 Stage IC1 4 Stage IC2 5 Stage IC3 6 Stage IIA 7 Stage IIB 8 Stage IIIA1 9 Stage IIIA1(i) 10 Stage IIIA1(ii) 11 Stage IIIA2 12 Stage IIIB 13 Stage IIIC 14 Stage IV 15 Stage IVA 16 Stage IVB Supplementary values: 99 Not available/inadequately described Collection and usage attributes Guide for use: The FIGO stage section should be filled out according to the 2013 definitions. Stage I Growth limited to the ovaries CODE 1 Stage IA Tumour limited to one ovary; no malignant cells in ascites or peritoneal washings. No tumour present on ovarian surface; capsule intact. CODE 2 Stage IB Tumour limited to both ovaries, capsule intact, no tumour on ovarian surface; no malignant cells in ascites or peritoneal washings. CODE 3 Stage IC1 Tumour limited to one or both ovaries or fallopian tubes with surgical spill. Stage II Tumour involving one or both ovaries with pelvic extension CODE 4 Stage IC2 Tumour limited to one or both ovaries or fallopian tubes, with capsule ruptured before surgery or tumour on ovarian surface. CODE 5 Stage IC3 Tumour limited to one or both ovaries or fallopian tubes, with malignant cells in the ascites or peritoneal washings. Stage II Tumour involving one or both ovaries with pelvic extension (below pelvic brim) CODE 6 Stage IIA Extension and/or implants on uterus and/or fallopian tubes. CODE 7 Stage IIB Extension to other pelvic intraperitoneal tissues. Stage III Tumour involving one or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes. CODE 8 Stage IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven). CODE 9 Stage IIIA1(i) Positive retroperitoneal lymph nodes only (cytologically or histologically proven), with metastasis up to 10 mm in greatest dimension. CODE 10 Stage IIIA1(ii) Positive retroperitoneal lymph nodes only (cytologically or histologically proven), with metastasis more than 10 mm in greatest dimension. CODE 11 Stage IIIA2 Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. CODE 12 Stage IIIB Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes. CODE 13 Stage IIIC Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumour to capsule of liver and spleen without parenchymal involvement of either organ). CODE 14 Stage IV Distant metastases, excluding peritoneal metastases. CODE 15 Stage IVA Distant metastases, excluding peritoneal metastases, with pleural effusion with positive cytology. CODE 16 Stage IVB Distant metastases, excluding peritoneal metastases, including parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity). Source and reference attributes Reference documents: Prat, J. Staging classification for cancer of the ovary, fallopian tube and peritoneum. International Journal of Gynecology and Obstetrics 2014, 124: 1-5. Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is only to be recorded for patients with ovarian cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. Data element attributes Collection and usage attributes Guide for use: Record the extent of the primary endometrial cancer as outlined by the International Federation of Gynecology and Obstetrics (FIGO) stage. This should be filled out according to 1988 definitions. Collection methods: To be sought from pathology reports or patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Prat, J. Staging classification for cancer of the ovary, fallopian tube and peritoneum. International Journal of Gynecology and Obstetrics 2014, 124: 1-5. Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person with cancer—distant metastatic cancer indicator, yes/no/not stated/inadequately described code N Identifying and definitional attributes Short name: Distant metastatic site indicator METeOR identifier: 545189 Registration status: Health, Standard 08/05/2014 Definition: An indicator of whether a primary cancer has spread to a distant site in the person with cancer, as represented by a code. Data Element Concept: Person with cancer—distant metastatic cancer indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data element attributes Collection and usage attributes Guide for use: Record whether a primary cancer has spread to a distant site or sites. This may be determined through diagnostic or other imaging or procedures. What is determined as a distant site will vary depending on the primary cancer type. Collection methods: Collect from patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Pecorelli, S. 25th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynecology & Obstetrics 2003, 83 (Supp 1): 1-230. RCPA (2011). Endometrial Cancer Structured Reporting Protocol (1st Edition 2011) Mutch, D G (2009). The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic Oncology. 115: 325–328 Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person with cancer—distant metastatic site(s) at diagnosis, code N[N] Obligation: Conditional, Maximum occurences: 20 Identifying and definitional attributes Short name: Distant metastatic site(s) at diagnosis METeOR identifier: 424239 Registration status: Health, Standard 08/05/2014 Definition: The anatomical position (topography) of the secondary or distant metastatic site(s) identified in the person with cancer at diagnosis, as represented by a code. Data Element Concept: Person with cancer—distant metastatic site(s) at diagnosis Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N[N] Maximum character length: 2 Permissible values: Value Meaning 1 Lung 2 Liver 3 Bowel 4 Bone 5 Brain 88 Other Supplementary values: 99 Metastatic spread indicated but site not stated/inadequately described Collection and usage attributes Guide for use: This code set represents common sites of cancer metastasis. Where multiple sites occur, all should be recorded. Source and reference attributes Reference documents: Pecorelli, S. 25th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynecology & Obstetrics 2003, 83 (Supp 1): 1-230 Endometrial Cancer Structured Reporting Protocol (1st Edition 2010) © RCPA 2010 The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas; Gynecologic Oncology 115 (2009) 325–328 Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be completed if Person with cancer—distant metastatic cancer indicator, yes/no/not stated/inadequately described code N indicates the presence of metastatic cancer. Data element attributes Collection and usage attributes Guide for use: Record sites of metastases. Where multiple sites occur, all should be recorded. Collection methods: Collect from patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Pecorelli, S. 25th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynecology & Obstetrics 2003, 83 (Supp 1): 1-230. RCPA (2011). Endometrial Cancer Structured Reporting Protocol (1st Edition 2011) Mutch, D G (2009). The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic Oncology. 115: 325–328 Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015 Prostate cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person with cancer—depth of myometrial invasion, total millimetres N[N] Obligation: Conditional Identifying and definitional attributes Short name: Depth of myometrial invasion Synonymous names: Depth of myometrial involvement METeOR identifier: 545243 Registration status: Health, Standard 08/05/2014 Definition: The depth of tumour invasion into the myometrium for a person with endometrial cancer, expressed in millimetres. Data Element Concept: Person with cancer—depth of myometrial invasion Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[N] Maximum character length: 2 Supplementary values: Value Meaning 97 Not applicable 98 Unknown 99 Not stated/inadequately described Unit of measure: Millimetre (mm) Collection and usage attributes Guide for use: Size in millimetres with valid values from 1 to 96. Source and reference attributes Submitting organisation: Cancer Australia Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is only to be recorded for patients with endometrial cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. Data element attributes Collection and usage attributes Guide for use: Record the depth of myometrial invasion in millimetres (mm). The depth of myometrial invasion is assessed on microscopic examination and is measured from the normal endometrium-myometrium interface (not the surface of the intracavity or exophytic tumour) to the deepest tumour infiltrative focus. The depth of myometrial invasion cannot exceed the myometrial thickness. Myometrial thickness ranges from 2 to 40 mm. A myometrial thickness of 5 mm or less is considered to be normal. Depth of myometrial invasion is a prognostic factor for endometrial cancer. The fractional myometrial invasion by tumour cells, i.e. the ratio of myometrial invasive depth to total normal myometrial thickness, is predictive of lymph node metastases in high risk endometrial cancers. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Hauth EA, Jaeger HJ, Libera H, Lange S, Forsting M 2007. MR imaging of the uterus and cervix in healthy women: determination of normal values. European Radiology 17:734 O'Connell LO, Fries MH, Zeringue E, Brehm W 1998. Triage of Abnormal Postmenopausal Bleeding: A comparison of endometrial biopsy and transvaginal sonohysterography versus fractional curettage with hysteroscopy. American Journal of Obstetrics & Gynecology 178:956-61 RCPA 2011. Endometrial Cancer Structured Reporting Protocol (1st Edition 2011). Sydney: Royal College of Pathologists of Australasia Weber AM, Belinson JL, Bradley LD, Piedmonte MR 1997. Vaginal ultrasonography versus endometrial biopsy in women with postmenopausal bleeding. American Journal of Obstetrics & Gynecology 177:924-9 Relational attributes Related metadata references: See also Person with cancer—myometrial thickness, total millimetres N[N] Health, Standard 08/05/2014 Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Unidades de medida

• mm

Descripción

Person with cancer—myometrial thickness, total millimetres N[N] Obligation: Conditional Identifying and definitional attributes Short name: Myometrial thickness METeOR identifier: 424269 Registration status: Health, Standard 08/05/2014 Definition: The total myometrial thickness for a person with endometrial cancer, expressed in millimetres. Data Element Concept: Person with cancer—myometrial thickness Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[N] Maximum character length: 2 Supplementary values: Value Meaning 97 Not applicable 98 Unknown 99 Not stated/inadequately described Unit of measure: Millimetre (mm) Collection and usage attributes Guide for use: Size in millimetres with valid values from 1 to 96. Source and reference attributes Submitting organisation: Cancer Australia Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is only to be recorded for patients with endometrial cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. Data element attributes Collection and usage attributes Guide for use: Record the total myometrial thickness in millimetres (mm). Depth of myometrial invasion is a prognostic factor for endometrial cancer. Myometrial thickness ranges from 2 to 40 mm. A myometrial thickness of 5 mm or less is considered to be normal. The fractional myometrial invasion by tumour cells, i.e. the ratio of myometrial invasive depth to total normal myometrial thickness, is predictive of lymph node metastases in high risk endometrial cancers. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Hauth EA, Jaeger HJ, Libera H, Lange S, Forsting M 2007. MR imaging of the uterus and cervix in healthy women: determination of normal values. European Radiology 17:734 O'Connell LO, Fries MH, Zeringue E, Brehm W 1998. Triage of Abnormal Postmenopausal Bleeding: A comparison of endometrial biopsy and transvaginal sonohysterography versus fractional curettage with hysteroscopy. American Journal of Obstetrics & Gynecology 178:956-61 RCPA 2011. Endometrial Cancer Structured Reporting Protocol (1st Edition 2011). Sydney: Royal College of Pathologists of Australasia Weber AM, Belinson JL, Bradley LD, Piedmonte MR 1997. Vaginal ultrasonography versus endometrial biopsy in women with postmenopausal bleeding. American Journal of Obstetrics & Gynecology 177:924-9 Relational attributes Related metadata references: See also Person with cancer—depth of myometrial invasion, total millimetres N[N] Health, Standard 08/05/2014 Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Unidades de medida

• mm

Descripción

Person with cancer—depth of cervical cancer invasion, total millimetres N[N] Obligation: Conditional Identifying and definitional attributes Short name: Depth of cervical cancer invasion METeOR identifier: 424275 Registration status: Health, Standard 08/05/2014 Definition: The depth of invasion of a cervical cancer tumour into the cervical wall for a person with cervical cancer, expressed in millimetres. Data Element Concept: Person with cancer—depth of cervical cancer invasion Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[N] Maximum character length: 2 Supplementary values: Value Meaning 97 Not applicable 98 Unknown 99 Not stated/inadequately described Unit of measure: Millimetre (mm) Collection and usage attributes Guide for use: Size in millimetres with valid values from 1 to 96. Source and reference attributes Submitting organisation: Cancer Australia Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is only to be recorded for patients with cervical cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. Data element attributes Collection and usage attributes Guide for use: Record the depth of invasion of cervical cancer into the cervical wall in millimetres (mm), where available from a pathology report. The depth of cervical wall invasion ranges from 0 to 30 mm. The depth of tumour invasion is an important prognostic indicator for cervical cancer. All macroscopically visible lesions, even with superficial invasion, are allocated to Stage Ib carcinomas. Collection methods: Collect from pathology reports or databases. Source and reference attributes Submitting organisation: The Australian e-Health Research Centre/CSIRO Reference documents: Pecorelli S 2003. 25th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynecology & Obstetrics 83(Supp 1): 1-230 Bertrand M Lickrish GM, Colgan TJ 1987. The anatomic distribution of cervical adenocarcinoma in situ: Implications for the treatment. American Journal of Obstetrics & Gynecology 157: 21-28 Wei J 2009. Pathology of Cervical Carcinoma. Global library of women's medicine. Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Unidades de medida

• mm

Descripción

Person with cancer—tumour outside primary site indicator, yes/no/not stated/inadequately described code N Identifying and definitional attributes Short name: Tumour outside primary site indicator METeOR identifier: 545382 Registration status: Health, Standard 08/05/2014 Definition: An indicator of whether there is macroscopic evidence of a tumour outside of the primary site of cancer in a person with cancer, as represented by a code. Data Element Concept: Person with cancer—tumour outside primary site indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data element attributes Collection and usage attributes Guide for use: Record whether there is evidence of macroscopic tumour outside of the primary site of cancer for both patients treated initially with surgery and non-surgical cases. In non-surgical cases, the extent of tumour outside the primary site may be assessed by imaging, for example using a CT scan, or diagnostic procedure, for example an ultrasound guided core biopsy. Collection methods: Collect from pathology reports or patient medical records. Comments: Although tumour size outside the primary site is not used in the staging process, it is a prognostic factor. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Pecorelli, S. 25th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynecology & Obstetrics 2003, 83(Supp 1): 1-230 Cancer Australia Project Working Group, 2010 Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person with cancer—tumour size outside primary site, code N Identifying and definitional attributes Short name: Tumour size outside primary site METeOR identifier: 424282 Registration status: Health, Standard 08/05/2014 Definition: The amount of macroscopic tumour outside of the primary site of cancer in a person with cancer, as represented by a code. Data Element Concept: Person with cancer—tumour size outside primary site Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Macroscopic disease less than or equal to 2 cm outside the primary tumour site 2 Macroscopic disease between 2 cm and less than 10 cm outside primary tumour site 3 Macroscopic disease equal to or greater than 10 cm outside the primary tumour site Supplementary values: 8 Unknown 9 Not stated/inadequately described Collection and usage attributes Guide for use: Use the appropriate value to indicate the size of macroscopic disease outside of the primary site of cancer. CODE 8 Unknown To be used if records have no indications of procedures (surgery or diagnostic biopsy) or imaging (such as CT scans) that would allow macroscopic spread to be seen. CODE 9 Not stated/inadequately described To be used if procedures or imaging that allow macroscopic spread to be seen have been undertaken but there is no indication of the size of the tumour outside of the primary site. Source and reference attributes Submitting organisation: Cancer Australia Data element attributes Collection and usage attributes Guide for use: Record the amount of macroscopic tumour outside of the primary site of cancer for both patients treated initially with surgery and non-surgical cases. In non-surgical cases, the extent of tumour outside the primary site may be assessed by imaging, for example using a CT scan, or diagnostic procedure, for example an ultrasound guided core biopsy. Collection methods: Collect from pathology reports or patient medical records. Comments: Although tumour size outside the primary site is not used in the staging process, it is a prognostic factor. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Pecorelli, S. 25th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynecology & Obstetrics 2003, 83(Supp 1): 1-230 Cancer Australia Project Working Group, 2010 Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person with cancer—multiple primary tumours indicator, yes/no code N Identifying and definitional attributes Short name: Multiple primary tumours indicator METeOR identifier: 519548 Registration status: Health, Standard 08/05/2014 Definition: An indicator of whether a person with cancer has multiple primary tumours, as represented by a code. Data Element Concept: Person with cancer—multiple primary tumours indicator Value domain attributes Representational attributes Representation class: Code Data type: Boolean Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Data element attributes Collection and usage attributes Guide for use: Record whether a person with cancer has multiple primary tumours, regardless of whether they are synchronous or metachronous. Patients with multiple primary tumours may have a worse prognosis or more extensive treatment than patients with a single tumour. In addition, the management and prognosis when multiple primary tumours are present may vary depending on whether the tumours are synchronous or metachronous. Source and reference attributes Submitting organisation: Cancer Australia Relational attributes Related metadata references: See also Person with cancer—multiple primary tumours descriptor, code N Health, Standard 08/05/2014 Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015 Lung cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

boolean

Descripción

Person with cancer—multiple primary tumours descriptor, code N Obligation: Conditional Identifying and definitional attributes Short name: Multiple primary tumours descriptor METeOR identifier: 429482 Registration status: Health, Standard 08/05/2014 Definition: Whether the multiple primary tumours in the person with cancer are synchronous or metachronous, as represented by a code. Data Element Concept: Person with cancer—multiple primary tumours descriptor Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Synchronous 2 Metachronous Supplementary values: 7 Not applicable, i.e. single primary tumour only 8 Number of primary tumours unknown 9 Multiple primary tumours present, but synchronicity not stated/inadequately described Collection and usage attributes Guide for use: Record the appropriate code at diagnosis, then update at the first appearance of a subsequent second primary where multiple tumours are discovered. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Breathnach OS & Skarin AT 2009. Multiple primary lung cancers. Wolters Kluwer Health, UpToDate Inc., Waltham, MA. Viewed 8 March 2011, http://www.uptodate.com/contents/multiple-primary-lung-cancers Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded if Person with cancer—multiple primary tumours indicator, yes/no code N indicates the presence of multiple primary tumours. Data element attributes Collection and usage attributes Guide for use: Synchronous primary tumours are detected simultaneously, either preoperatively or in the resected specimen. Metachronous primary tumours are detected after a time interval between detection of the first lesion and detection of a subsequent primary lesion. Collection methods: This information should be sought from the patient's pathology report and medical record. Comments: Patients with multiple primary tumours may have a worse prognosis or more extensive treatment than patients with a single tumour. In addition, the management and prognosis when multiple primary tumours are present may vary depending on whether the tumours are synchronous or metachronous. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Breathnach OS & Skarin AT 2009. Multiple primary lung cancers. Wolters Kluwer Health, UpToDate Inc., Waltham, MA. Viewed 8 March 2011, http://www.uptodate.com/contents/multiple-primary-lung-cancers Relational attributes Related metadata references: See also Person with cancer—multiple primary tumours indicator, yes/no code N Health, Standard 08/05/2014 Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015 Lung cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Person—tissue sample collected indicator, yes/no code N Maximum occurences: 30 Identifying and definitional attributes Short name: Tissue sample collected indicator METeOR identifier: 446565 Registration status: Health, Standard 08/05/2014 Definition: An indicator of whether a tissue sample has been collected from a person, as represented by a code. Data Element Concept: Person—tissue sample collected indicator Value domain attributes Representational attributes Representation class: Code Data type: Boolean Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Data element attributes Collection and usage attributes Guide for use: Record whether a tissue sample has been collected from a person. This includes tissue that has been collected for either clinical or research purposes and stored in any format, including tissue samples that have been snap frozen, stored with OCT (optimum cutting temperature compound), FFPE (formalin fixed, paraffin embedded), and if RNA and/or DNA has been extracted from tissue and stored. Collection methods: Collect from medical, laboratory or biobank records. Source and reference attributes Submitting organisation: Cancer Australia Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

boolean

Descripción

Organisation—organisation name, text X[X(199)] Obligation: Conditional, Maximum occurences: 10 Identifying and definitional attributes Short name: Organisation name Synonymous names: Business name; Entity name METeOR identifier: 453823 Registration status: Health, Standard 08/05/2014 Early Childhood, Standard 09/03/2012 Indigenous, Endorsed 13/03/2015 Disability, Standard 13/08/2015 Community Services (retired), Standard 06/02/2012 Definition: The full title of an organisation's name by which it trades or is recognised, as represented by text. Data Element Concept: Organisation—organisation name Value domain attributes Representational attributes Representation class: Text Data type: String Format: X[X(199)] Maximum character length: 200 Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded when the data element Person—tissue sample collected indicator, yes/no code N indicates that a tissue sample has been collected. DSS specific information: Use this data element to record the name of the laboratory or biobank in which a tissue sample is stored. Collect this data element in conjunction with Person—tissue sample collected indicator, yes/no code N. Data element attributes Collection and usage attributes Guide for use: An organisation may have multiple names. Naming standards for incorporated companies are defined in the Australian Securities and Investments Commission (ASIC), Schedule 6 of the Corporation Regulations. Collection methods: If special characters or symbols form part of the name they should be included. This includes all characters from the standard printable ASCII character set such as the letters A-Z, hyphens, commas, apostrophes, @, # etc, as well as the non-standard or extended ASCII characters such as ü, á, é, ®, ™etc. Mixed case should be used rather than upper case only. Source and reference attributes Submitting organisation: Australian Institute of Health and Welfare Origin: Standards Australia 2006. AS 4590—2006 Interchange of client information. Sydney: Standards Australia. Relational attributes Related metadata references: Supersedes Service provider organisation (name)—organisation name, text X[X(199)] Health, Superseded 08/05/2014, Early Childhood, Superseded 09/03/2012, Indigenous, Archived 13/03/2015, Community Services (retired), Superseded 06/02/2012 Implementation in Data Set Specifications: Early Childhood Education and Care: Aggregate NMDS 2015 Early Childhood, Standard 01/06/2015 Early Childhood Education and Care: Unit Record Level NMDS 2015 Early Childhood, Standard 01/06/2015 Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015 Indigenous primary health care DSS 2015- Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Mental health organisation details cluster Health, Standard 13/11/2014 Organisation details data dictionary Disability, Standard 13/08/2015 Community Services (retired), Standard 06/02/2012

Tipo de datos

text

Descripción

Medical specialist—surgical specialty, initial gynaecological surgical speciality code N[N] Obligation: Conditional, Maximum occurences: 10 Identifying and definitional attributes Short name: Surgical specialty gynaecological cancer METeOR identifier: 424298 Registration status: Health, Standard 08/05/2014 Definition: The medical specialty of the surgeon who performed surgery for gynaecological cancer treatment, as represented by a code. Data Element Concept: Medical specialist—surgical specialty Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N[N] Maximum character length: 2 Permissible values: Value Meaning 1 Gynaecological oncologist 2 Gynaecologist 3 General surgeon 8 Other Supplementary values: 98 Unknown Collection and usage attributes Guide for use: CODE 1 Gynaecological oncologist A specialist in obstetrics and gynaecology, awarded the Fellowship of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), having completed a formal three-year training program in gynaecological cancer care and passed the examination for the Certificate of Gynaecological Oncology CGO). CODE 2 Gynaecologist A specialist in obstetrics and gynaecology awarded the Fellowship of RANZCOG, having completed advanced training prescribed or approved by the Council and who furnish to the Council satisfactory evidence of completion of such advanced training. CODE 3 General surgeon A specialist in surgery, having satisfactorily undertaken the Royal Australasian College of Surgeons (RACS) Fellowship Examination to ensure that attainment of Fellowship standards. CODE 8 Other Other medical practitioners with no specialist surgical/gynaecological cancer training. Comments: Justification: Provides data about patterns of care/management. Source and reference attributes Reference documents: Australian Cancer Network and National Breast Cancer Centre. Clinical practice guidelines for the management of women with epithelial ovarian cancer. NBCC. 2004. Royal Australasian College of Surgeon (RACS) and Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is only to be recorded for patients who have undergone surgery relating to their initial course of treatment for gynaecological cancer. Data element attributes Collection and usage attributes Guide for use: Record the medical specialty of the surgeon who performed surgery for gynaecological cancer during the initial course of treatment. Collection methods: Collect from patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Australian Cancer Network and National Breast Cancer Centre. Clinical practice guidelines for the management of women with epithelial ovarian cancer. NBCC. 2004 Royal Australasian College of Surgeon (RACS) and Royal Australian College of Obstetricians and Gynaecologists Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Cancer treatment—post-initial surgery residual tumour size category, code N Obligation: Conditional, Maximum occurences: 20 Identifying and definitional attributes Short name: Tumour residual post-surgery size category METeOR identifier: 424302 Registration status: Health, Standard 08/05/2014 Definition: The size of the residual tumour remaining after the initial surgery for cancer treatment, as represented by a code. Data Element Concept: Cancer treatment—post-initial surgery residual tumour size Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Microscopic but no macroscopic residual disease 2 Residual tumour less than 0.5 cm 3 Residual tumour between 0.5 cm and less than 1 cm 4 Residual tumour between 1 cm and 2 cm 5 Residual tumour greater than 2 cm Supplementary values: 7 Not applicable 8 Unknown/unable to be assessed 9 Not stated/inadequately described Collection and usage attributes Guide for use: This code outlines categories for the largest diameter of tumour residual implants after cancer treatment. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Pecorelli, S. 25th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynecology & Obstetrics 2003, 83(Supp 1): 1-230. Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded then the data element Cancer treatment—residual (R) tumour indicator, yes/no code N indicates the presence of residual tumour after surgery. Data element attributes Collection and usage attributes Guide for use: Record the size of the largest tumour residual remaining after the initial surgery for cancer treatment. The tumour residual size is the diameter of largest residual implants remaining after surgery. Collection methods: Collect from patient medical records. Comments: The residual tumour size after the initial surgery is a prognostic indicator that will impact later treatment pathways. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Pecorelli, S. 25th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynecology & Obstetrics 2003, 83(Supp 1): 1-230. Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Cancer treatment—residual (R) tumour indicator, yes/no code N Obligation: Conditional Identifying and definitional attributes Short name: Residual tumour indicator METeOR identifier: 430267 Registration status: Health, Standard 08/05/2014 Definition: An indicator of whether residual tumour is present after the course of treatment for cancer, as represented by a code. Data Element Concept: Cancer treatment—residual (R) tumour indicator Value domain attributes Representational attributes Representation class: Code Data type: Boolean Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded for patients with ovarian cancer and stage IV endometrial cancer when surgical treatment for gynaecological cancer has been completed. Data element attributes Collection and usage attributes Guide for use: Record the presence of residual tumour on completion of the course of treatment for cancer. In some cases treated with surgery and/or neoadjuvant therapy, residual tumour will be present at the primary site after treatment because of incomplete resection or local and regional disease extending beyond the scope of resection. Collection methods: This information should be sought from the patient's medical record, referral letters or attending medical clinician. Comments: The presence of residual tumour may indicate the effect of treatment, influence further treatment decisions, and be a strong predictor of prognosis. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: American Joint Committee on Cancer 2010. AJCC Cancer Staging Manual, 7th edition. Springer: New York Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015 Lung cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

boolean

Descripción

Cancer treatment—primary surgical treatment complication indicator, yes/no/unknown code N Identifying and definitional attributes Short name: Surgical treatment complication indicator Synonymous names: Critical event indicator METeOR identifier: 546455 Registration status: Health, Standard 08/05/2014 Definition: An indicator of the occurrence of treatment complications within 30 days of primary surgery for cancer treatment, as represented by a code. Data Element Concept: Cancer treatment—primary surgical treatment complication indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 8 Unknown Data element attributes Collection and usage attributes Guide for use: Record the whether there were any critical events/treatment complications within 30 days of primary surgery for cancer treatment. These include: · Unplanned return to theatre · Death within 30 days of surgery · Post-operative fistula · Intra-operative haemorrhage (more than 6 units of transfusion) · Pulmonary embolism · Unplanned transfer to intensive care unit (ICU) · Post-operative hospital stay of greater than 21 days Collection methods: Collect from medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Gynaecology Oncology Subspecialty Practice Improvement Critical Project (GO SPICE) Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Cancer treatment—treatment complication type, cancer-related primary surgery complication type code N[N] Obligation: Conditional, Maximum occurences: 10 Identifying and definitional attributes Short name: Surgical treatment complication type Synonymous names: Critical event type METeOR identifier: 424310 Registration status: Health, Standard 08/05/2014 Definition: The type of treatment complication/s arising within 30 days of undergoing surgical treatment for cancer, as represented by a code. Data Element Concept: Cancer treatment—treatment complication type Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N[N] Maximum character length: 2 Permissible values: Value Meaning 1 Unplanned return to theatre 2 Death within 30 days of surgery 3 Post-operative fistula 4 Intra-operative haemorrhage (greater than 6 units of transfusion) 5 Pulmonary embolism 6 Unplanned transfer to intensive care unit (ICU) 7 Post-operative stay greater than 21 days 88 Other complication or critical event Supplementary values: 98 Unknown 99 Not stated/inadequately described Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Gynaecology Oncology Subspecialty Practice Improvement Critical Project (GO SPICE) Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded when Cancer treatment—primary surgical treatment complication indicator, yes/no/unknown code N indicates the presence of a treatment complication. Data element attributes Collection and usage attributes Guide for use: Record the type of any treatment complications that occur within 30 days of primary surgery. If multiple events occur, all events should be recorded. Collection methods: Collect from medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Gynaecology Oncology Subspecialty Practice Improvement Critical Project (GO SPICE) Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Cancer treatment—gynaecological cancer post-radiotherapy complication indicator, yes/no/unknown code N Obligation: Conditional Identifying and definitional attributes Short name: Radiotherapy treatment complication indicator METeOR identifier: 546597 Registration status: Health, Standard 08/05/2014 Definition: An indicator of the presence of treatment complications within 30 days of a course of radiotherapy for gynaecological cancer, as represented by a code. Data Element Concept: Cancer treatment—gynaecological cancer post-radiotherapy complication indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 8 Unknown Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element should be recorded in relation to the primary course of treatment for gynaecological cancer. DSS specific information: This relates to the primary course of treatment for gynaecological cancer. Data element attributes Collection and usage attributes Guide for use: Record whether there are any treatment complications within 30 days of a course of radiotherapy for gynaecological cancer. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: NBOCC Working Group, 2008  Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Cancer treatment—treatment complication type, gynaecological cancer-related radiotherapy code N Obligation: Conditional, Maximum occurences: 10 Identifying and definitional attributes Short name: Radiotherapy treatment complication type METeOR identifier: 424314 Registration status: Health, Standard 08/05/2014 Definition: The type (or types) of treatment complication occurring within 30 days of radiotherapy for women with gynaecological cancer, as represented by a code. Context: For monitoring side effects of radiotherapy in 30 days post-treatment. Data Element Concept: Cancer treatment—treatment complication type Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Bowel obstruction requiring surgery 2 Fistula requiring stoma formation 3 Pelvic insufficiency 8 Other Supplementary values: 9 Not stated/inadequately described Source and reference attributes Submitting organisation: Cancer Australia Reference documents: NBOCC Working Group, 2008  Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element should be recorded when Cancer treatment—gynaecological cancer post-radiotherapy complication indicator, yes/no/unknown code N indicates the presence of a radiotherapy related treatment complication. Data element attributes Collection and usage attributes Guide for use: Record the code for the type/s of treatment complication/s that occur within 30 days of the primary course of radiotherapy for gynaecological cancer. This item can be recorded multiple times to account for multiple treatment complications. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: NBOCC Working Group, 2008  Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Cancer treatment—treatment complication type, text X[X(149)] Obligation: Conditional, Maximum occurences: 10 Identifying and definitional attributes Short name: Treatment complication description METeOR identifier: 467640 Registration status: Health, Standard 08/05/2014 Definition: The type of treatment complication (or complications) experienced by a person with cancer during their treatment for cancer and attributed to that treatment, as represented by text. Data Element Concept: Cancer treatment—treatment complication type Value domain attributes Representational attributes Representation class: Text Data type: String Format: X[X(149)] Maximum character length: 150 Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded when either Cancer treatment—treatment complication type, gynaecological cancer-related radiotherapy code N or Cancer treatment—treatment complication type, cancer-related primary surgery complication type code N[N] indicates an 'Other' type of treatment complication. Data element attributes Collection and usage attributes Guide for use: Record any immediate or short-term treatment complications (adverse events or toxicities) that were experienced by a person with cancer during their treatment for cancer. This includes any adverse events or treatment complications taking place within 30 days of treatment. Collection methods: Collect from patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Relational attributes Related metadata references: See also Cancer treatment—treatment complication outcome, code N Health, Standard 04/02/2015 See also Patient—immediate/short term treatment complication indicator, yes/no/not applicable/unknown/not stated/inadequately described code N Health, Standard 14/05/2015 See also Patient—treatment complication date, DDMMYYYY Health, Standard 04/02/2015 Implementation in Data Set Specifications: Adolescent and young adult cancer (clinical) DSS Health, Standard 14/05/2015 Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

text

Descripción

Cancer treatment—systemic therapy treatment modification indicator, yes/no/unknown code N Obligation: Conditional Identifying and definitional attributes Short name: Systemic therapy modification indicator METeOR identifier: 546764 Registration status: Health, Standard 08/05/2014 Definition: An indicator of whether there was modification made to a patient's planned systemic therapy treatment for cancer, as represented by a code. Data Element Concept: Cancer treatment—systemic therapy treatment modification indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 8 Unknown Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded for patients who have undergone systemic therapy as part of their cancer treatment. This includes chemotherapy, hormone therapy and immunotherapy. Data element attributes Collection and usage attributes Guide for use: Record whether there was a modification made to systemic therapy treatment from the initial treatment plan or systemic therapy schedule for a course of cancer treatment. Systemic therapy encompasses chemotherapy, hormone therapy and immunotherapy and modifications include (but are not limited to): · Dose decrease · Drug omission · Drug delivery interval increase · Dose increase · Drug introduction · Drug delivery interval decrease Treatment modification is often due to a patient's response to treatment or a change in the extent or pathway of the disease. Collection methods: Collect from patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Cancer Australia Working Group, 2010. Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Cancer treatment—treatment modification type for cancer-related systemic therapy, code N[N] Obligation: Conditional, Maximum occurences: 10 Identifying and definitional attributes Short name: Systemic therapy modification type METeOR identifier: 424306 Registration status: Health, Standard 08/05/2014 Definition: The type of change to a cancer patient's systemic therapy treatment plan, as represented by a code. Data Element Concept: Cancer treatment—treatment plan modification Value domain attributes Representational attributes Representation class: Code Data type: String Format: N[N] Maximum character length: 2 Permissible values: Value Meaning 01 Dose decrease 02 Drug omission 03 Drug delivery interval increase 04 Dose increase 05 Drug introduction 06 Drug delivery interval decrease 07 Dose increase and interval decrease 88 Other Supplementary values: 99 Not stated/inadequately described Collection and usage attributes Guide for use: Systemic therapy encompasses chemotherapy, hormone therapy and immunotherapy. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Cancer Australia Working Group, 2010. Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded when Cancer treatment—systemic therapy treatment modification indicator, yes/no/unknown code N indicates a modification to planned systemic therapy treatment. Data element attributes Collection and usage attributes Guide for use: Record the type of modification made to systemic therapy treatment from the initial treatment plan or systemic therapy schedule for a course of cancer treatment. Systemic therapy encompasses chemotherapy, hormone therapy and immunotherapy. Collection methods: Collect from patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Cancer Australia Working Group, 2010. Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

text

Descripción

Cancer treatment—treatment plan modification, text X[X(149)] Obligation: Conditional, Maximum occurences: 10 Identifying and definitional attributes Short name: Treatment plan modification description METeOR identifier: 568890 Registration status: Health, Standard 08/05/2014 Definition: A change made to the patient's cancer treatment plan, as represented by text. A cancer treatment plan may often change due to the patient's response to treatment or a change in the extent or pathway of the disease. Data Element Concept: Cancer treatment—treatment plan modification Value domain attributes Representational attributes Representation class: Text Data type: String Format: X[X(149)] Maximum character length: 150 Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded when Cancer treatment—treatment modification type for cancer-related systemic therapy, code N[N] indicates an 'Other' type of treatment modification. Data element attributes Collection and usage attributes Guide for use: Record a textual description of the change (or changes) made to the patient's cancer related treatment. This may include changes to the type of treatment, the dosage of treatment or the frequency of treatment. Collection methods: Collect from patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Relational attributes Implementation in Data Set Specifications: Adolescent and young adult cancer (clinical) DSS Health, Standard 14/05/2015 Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

text

Descripción

Cancer treatment—primary course of chemotherapy delay indicator, yes/no/unknown code N Obligation: Conditional, Maximum occurences: 5 Identifying and definitional attributes Short name: Delay in primary course of chemotherapy indicator METeOR identifier: 542950 Registration status: Health, Standard 08/05/2014 Definition: An indicator of whether the primary course of chemotherapy for cancer treatment has been delayed, as represented by a code. Data Element Concept: Cancer treatment—primary course of chemotherapy delay indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 8 Unknown Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded for patients who have undergone chemotherapy as part of their cancer treatment. Data element attributes Collection and usage attributes Guide for use: Record if the planned course of primary chemotherapy has been delayed. Collection methods: Collect from patient medical records. Record for a person undergoing chemotherapy as part of their cancer treatment. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Cancer Australia Working Group, 2010. Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Cancer treatment—primary course of chemotherapy delay reason, code N Obligation: Conditional, Maximum occurences: 10 Identifying and definitional attributes Short name: Primary course of chemotherapy delay reason METeOR identifier: 424458 Registration status: Health, Standard 08/05/2014 Definition: The reason for a delay in the primary course of chemotherapy for cancer treatment, as represented by a code. Data Element Concept: Cancer treatment—primary course of chemotherapy delay reason Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Delay due to toxicity 2 Delay due to other complication 3 Delay due to patient decision 8 Other Supplementary values: 9 Not stated/inadequately described Source and reference attributes Submitting organisation: Cancer Australia Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded when Cancer treatment—chemotherapy delay indicator, yes/no/unknown code N indicates a delay in planned chemotherapy treatment. Data element attributes Collection and usage attributes Guide for use: Record the reason that there was a delay in the primary course of chemotherapy. Collection methods: Collect from patient medical records. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: Cancer Australia Working Group, 2010. Relational attributes Implementation in Data Set Specifications: Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Cancer treatment—cancer treatment type, code N[N] Obligation: Conditional, Maximum occurences: 5 Identifying and definitional attributes Short name: Cancer treatment type METeOR identifier: 561618 Registration status: Health, Standard 08/05/2014 Definition: The type of treatment administered during the course of treatment for cancer, as represented by a code. Data Element Concept: Cancer treatment—cancer treatment type Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N[N] Maximum character length: 2 Permissible values: Value Meaning 1 Surgery only 2 Radiotherapy only 3 Systemic agent therapy only 4 Surgery and radiotherapy 5 Surgery and systemic agent therapy 6 Radiotherapy and systemic agent therapy 7 Surgery, radiotherapy and systemic agent therapy Supplementary values: 97 Not applicable—treatment was not administered 98 Unknown whether treatment was administered 99 Treatment was administered but the type was not stated/inadequately described Collection and usage attributes Guide for use: More than one treatment type may be administered during a course of cancer treatment; select the appropriate code value. Systemic agent therapy refers to: · chemotherapy · hormone therapy · immunotherapy Surgery includes: · surgical procedure for cancer · systemic therapy procedure involving surgery A systemic therapy procedure is a medical, surgical or radiation procedure that has an effect on the hormonal or immunologic balance of the patient. Treatments other than surgery, radiotherapy or systemic agent therapy administered as part of the treatment are recorded separately. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: American College of Surgeons 2002. Facility Oncology Registry Data Standards (FORDS), 2009 revision. Commission on Cancer, 28E Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded for a patient having a first recurrence of cancer. All treatments administered to the patient during the first recurrence of cancer should be recorded. DSS specific information: This data element is to be recorded separately for the primary course of treatment and treatment for the first recurrence of cancer. All treatments administered to the patient as part of the primary course of treatment for the first recurrence of cancer should be recorded. Data element attributes Collection and usage attributes Guide for use: All treatments administered to the patient during the course of cancer treatment should be recorded. When the patient has received treatment for cancer and codes 1 to 7 are recorded, the relevant treatment information for each treatment modality should also be collected. Cancer-directed treatments administered to the patient during the course of treatment that cannot be characterised as surgery, radiotherapy or systemic therapy according to the definitions in this data set specification, are recorded separately in the data element Other cancer treatment description Collection methods: This information should be obtained from the patient's medical record. Comments: The collection of specific treatment information is useful to evaluate patterns of care, the effectiveness of different treatment modalities, and treatment by patient outcome. Source and reference attributes Origin: Commission on Cancer, American College of Surgeons New South Wales Health Department Reference documents: American College of Surgeons 1998. Standards of the Commission on Cancer: Registry Operations and Data Standards (ROADS), Volume II. Commission on Cancer Public Health Division 2001. NSW Clinical Cancer Data Collection for Outcomes and Quality. Data Dictionary Version 1. Sydney: NSW Health Department Relational attributes Related metadata references: Supersedes Cancer treatment—cancer treatment type, code N[N] Health, Superseded 08/05/2014 See also Cancer treatment—other cancer treatment, text X[X(149)] Health, Standard 08/05/2014 See also Chemotherapy for cancer cluster Health, Standard 08/05/2014 See also Hormone therapy for cancer cluster Health, Standard 08/05/2014 See also Immunotherapy for cancer cluster Health, Standard 08/05/2014 See also Radiotherapy for cancer cluster Health, Standard 08/05/2014 See also Surgery for cancer cluster Health, Standard 14/05/2015 See also Surgery for cancer cluster Health, Superseded 14/05/2015 See also Systemic therapy procedure for cancer cluster Health, Standard 08/05/2014 Implementation in Data Set Specifications: Adolescent and young adult cancer (clinical) DSS Health, Standard 14/05/2015 Cancer (clinical) DSS Health, Standard 14/05/2015 Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer

Descripción

Cancer treatment—other cancer treatment, text X[X(149)] Obligation: Conditional, Maximum occurences: 10 Identifying and definitional attributes Short name: Other cancer treatment description METeOR identifier: 561623 Registration status: Health, Standard 08/05/2014 Definition: The cancer-directed treatment administered during the course of treatment for cancer, other than surgery, radiotherapy or systemic therapy, as represented by text. Data Element Concept: Cancer treatment—other cancer treatment Value domain attributes Representational attributes Representation class: Text Data type: String Format: X[X(149)] Maximum character length: 150 Source and reference attributes Submitting organisation: Cancer Australia Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is to be recorded for a patient having treatment that cannot be defined as surgery, radiotherapy or systemic therapy according to the definitions of those data items in this data set specification. DSS specific information: This data element is to be used to describe treatment, other than surgery, radiotherapy or systemic therapy, used to treat a first recurrence of gynaecological cancer. Data element attributes Collection and usage attributes Guide for use: This data item is to record cancer-directed treatments that cannot be appropriately assigned to the specific treatment codes in the cancer treatment data items for surgery, radiotherapy, systemic therapy agents and systemic therapy procedures. Cancer-directed treatments refer to those treatments that destroy or modify cancer tissue anywhere in the body. The exception to this is treatments for hematopoietic diseases (refer to additional notes below). Cancer-directed treatments may be palliative (to control symptoms, alleviate pain, or make the patient more comfortable) or curative. Record all other treatments administered during the course of treatment. Each treatment event delivered to the patient should be recorded; multiple entries are permitted. Record antibody treatments, vaccine treatments, and those targeted therapies that use drugs or substances other than chemotherapy agents in this data item. Targeted therapies using chemotherapy agents are recorded in the data items for chemotherapy. Targeted therapies are treatments that use drugs or other substances to identify and attack specific cancer cells. Do not record ancillary drugs. For example, allopurinol, which is commonly used as prophylaxis with chemotherapy agents to prevent severe hyperuricemia. A list of drugs regarded as ancillary is available in the SEER*Rx-Interactive Antineoplastic Drugs Database Version 1.4.1. Treatment events may include (for example): · Treatment unique to hematopoietic diseases, for example, phlebotomy, transfusions or aspirin. ONLY record aspirin therapy used to thin the blood for symptomatic control of thrombocythemia. Do not record aspirin used for pain or cardiovascular protection. · Embolisation that is performed using alcohol as an embolising agent or for embolisation to a site other than the liver where the embolising agent is unknown. Embolisation using chemotherapeutic agents is coded separately with chemotherapy, and embolisation using a radioactive agent or seeds is coded with brachytherapy-radiation treatment. · Any experimental or newly developed treatment that cannot be appropriately assigned to other specific treatment data items. · A double-blind clinical trial. Record the treatment actually administered to the patient in the appropriate treatment data item when the double-blind trial code is broken. · Cancer treatments administered by non-medical personnel. This includes unconventional methods whether administered as single therapy or in combination with conventional therapies. Record alternative therapies only if the patient doesn’t receive any other type of treatment. Collection methods: The information should be obtained from the patient’s medical record. Comments: Information on other cancer treatments is used to describe and evaluate the quality of care and treatment practices. Source and reference attributes Submitting organisation: Cancer Australia Reference documents: American College of Surgeons 2002. Facility Oncology Registry Data Standards (FORDS), 2009 revision. Commission on Cancer American College of Surgeons 1998. Standards of the Commission on Cancer: Registry Operations and Data Standards (ROADS), Volume II. Commission on Cancer Johnson CH & Adamo M (Editors) 2007. SEER Program Coding and Staging Manual 2007, MD 2008 revision. Bethesda:National Cancer Institute, NIH Publication number 07-5581 Relational attributes Related metadata references: See also Cancer treatment—cancer treatment type, code N[N] Health, Standard 08/05/2014 Supersedes Cancer treatment—other cancer treatment, text [X(150)] Health, Superseded 08/05/2014 See also Cancer treatment—surgical procedure for prostate cancer, code N Health, Standard 14/05/2015 Implementation in Data Set Specifications: Adolescent and young adult cancer (clinical) DSS Health, Standard 14/05/2015 Cancer (clinical) DSS Health, Standard 14/05/2015 Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

text

Descripción

Cancer treatment—outcome of treatment, code N.N Obligation: Conditional, Maximum occurences: 5 Identifying and definitional attributes Short name: Outcome of treatment METeOR identifier: 561665 Registration status: Health, Standard 08/05/2014 Definition: The response of the tumour at the completion of the course of treatment for cancer, as represented by a code. Data Element Concept: Cancer treatment—outcome of treatment Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N.N Maximum character length: 2 Permissible values: Value Meaning 1.0 Complete response/no evidence of disease 2.1 Partial response 2.2 Stable or static disease 2.3 Progressive disease Supplementary values: 7.0 Not assessed or unable to be assessed 8.0 Unknown 9.0 Not stated/inadequately described Collection and usage attributes Guide for use: The outcome of treatment is recorded at the completion of the course of treatment for the cancer. CODE 1.0 Complete response/no evidence of disease Complete disappearance of all measurable disease, including tumour markers, for at least four weeks. No new lesions or new evidence of disease. For breast cancer, this reflects "No evidence of disease". CODE 2.1 Partial response A decrease by at least 50% of the sum of the products of the maximum diameter and perpendicular diameter of all measurable lesions, for at least four weeks. No new lesions or worsening of disease. CODE 2.2 Stable or static disease No change in measurable lesions qualifying as partial response or progression and no evidence of new lesions. CODE 2.3 Progressive disease An increase by at least 25% of the sum of the products of the maximum diameter and a perpendicular diameter of any measurable lesion, or the appearance of new lesions. CODE 9.0 Not stated/inadequately described The tumour was assessed but the percentage of increase or decrease in the tumour size is not stated or is inadequately described. Source and reference attributes Submitting organisation: Cancer Australia Data set specification specific attributes Gynaecological cancer (clinical) DSS Conditional obligation: This data element is conditional on a patient completing treatment for their first recurrence of cancer. DSS specific information: This data element is to be recorded for patients who have completed their primary course of treatment or treatment for the first recurrence of cancer. For patients who have completed treatment for their first recurrence of cancer this should be recorded multiple times, once in relation to their primary course of treatment and once in relation to treatment for the first recurrence of cancer. Data element attributes Collection and usage attributes Collection methods: This information should be obtained from the patient's medical record. Comments: Information regarding the outcome of treatment is required for patient follow-up and outcomes studies. Source and reference attributes Submitting organisation: Cancer Australia Origin: New South Wales Health Department Reference documents: Public Health Division 2001. NSW Clinical Cancer Data Collection for Outcomes and Quality: Data Dictionary, Version 1. Sydney:NSW Health Department Relational attributes Related metadata references: See also Cancer treatment—date of treatment outcome, DDMMYYYY Health, Standard 04/02/2015 Supersedes Cancer treatment—outcome of treatment, code N.N Health, Superseded 08/05/2014 Implementation in Data Set Specifications: Cancer (clinical) DSS Health, Standard 14/05/2015 Gynaecological cancer (clinical) DSS Health, Standard 14/05/2015

Tipo de datos

integer